CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-12-20
DOI
https://doi.org/10.1080/14796694.2024.2441649
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan

Takahiro Nakayama, Linghua Xu, Yukio Muramatsu
1 links
Future Oncology
Advanced Breast Cancer Therapies
article

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan

Takahiro Nakayama, Linghua Xu, Yukio Muramatsu
article en

Abstract

No abstract available for this paper.
Future OncologyVol. 21(3)
Pfizer (Japan) (JP), Osaka International Cancer Institute (JP)
Pfizer, Japan Society of Clinical Oncology
Good health and well-being
Openalex Percentile: Top 57%
Advanced Breast Cancer Therapies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan — Takahiro Nakayama, Linghua Xu, et al. · Future Oncology (2024) | TGRS Research Map | TGRS